Caxton Associates (New York)’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $590K | Buy |
+1,797
| New | +$590K | 0.02% | 299 |
|
|
2024
Q3 | – | Sell |
-3,785
| Closed | -$1.03M | – | 527 |
|
|
2024
Q2 | $1.03M | Buy |
+3,785
| New | +$1.03M | 0.04% | 241 |
|
|
2024
Q1 | – | Sell |
-10,677
| Closed | -$3.45M | – | 465 |
|
|
2023
Q4 | $3.45M | Buy |
10,677
+8,813
| +473% | +$2.85M | 0.18% | 72 |
|
|
2023
Q3 | $668K | Buy |
+1,864
| New | +$668K | 0.09% | 206 |
|
|
2023
Q1 | – | Sell |
-2,822
| Closed | -$1.19M | – | 496 |
|
|
2022
Q4 | $1.19M | Buy |
2,822
+2,003
| +245% | +$842K | 0.08% | 79 |
|
|
2022
Q3 | $342K | Sell |
819
-488
| -37% | -$204K | 0.05% | 288 |
|
|
2022
Q2 | $647K | Buy |
1,307
+754
| +136% | +$373K | 0.06% | 197 |
|
|
2022
Q1 | $311K | Sell |
553
-129
| -19% | -$72.5K | 0.03% | 328 |
|
|
2021
Q4 | $515K | Buy |
+682
| New | +$515K | 0.05% | 244 |
|
|
2021
Q3 | – | Sell |
-1,234
| Closed | -$795K | – | 429 |
|
|
2021
Q2 | $795K | Buy |
1,234
+253
| +26% | +$163K | 0.09% | 83 |
|
|
2021
Q1 | $560K | Buy |
+981
| New | +$560K | 0.05% | 121 |
|
|
2017
Q3 | – | Sell |
-2,903
| Closed | -$657K | – | 447 |
|
|
2017
Q2 | $657K | Buy |
+2,903
| New | +$657K | 0.03% | 180 |
|